Logo image of QTTB

Q32 BIO INC (QTTB) Stock Fundamental Analysis

NASDAQ:QTTB - Nasdaq - US7469641051 - Common Stock - Currency: USD

2.57  +0.14 (+5.76%)

After market: 2.45 -0.12 (-4.67%)

Fundamental Rating

2

QTTB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. The financial health of QTTB is average, but there are quite some concerns on its profitability. QTTB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

QTTB had negative earnings in the past year.
In the past year QTTB has reported a negative cash flow from operations.
QTTB had negative earnings in each of the past 5 years.
In the past 5 years QTTB always reported negative operating cash flow.
QTTB Yearly Net Income VS EBIT VS OCF VS FCFQTTB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -47.51%, QTTB perfoms like the industry average, outperforming 48.67% of the companies in the same industry.
Looking at the Return On Equity, with a value of -271.46%, QTTB is doing worse than 73.36% of the companies in the same industry.
Industry RankSector Rank
ROA -47.51%
ROE -271.46%
ROIC N/A
ROA(3y)-60.34%
ROA(5y)-52.65%
ROE(3y)-71.33%
ROE(5y)-63.97%
ROIC(3y)N/A
ROIC(5y)N/A
QTTB Yearly ROA, ROE, ROICQTTB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

QTTB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QTTB Yearly Profit, Operating, Gross MarginsQTTB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

5

2. Health

2.1 Basic Checks

QTTB does not have a ROIC to compare to the WACC, probably because it is not profitable.
QTTB has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, QTTB has less shares outstanding
There is no outstanding debt for QTTB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
QTTB Yearly Shares OutstandingQTTB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
QTTB Yearly Total Debt VS Total AssetsQTTB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

QTTB has an Altman-Z score of -3.75. This is a bad value and indicates that QTTB is not financially healthy and even has some risk of bankruptcy.
QTTB has a Altman-Z score of -3.75. This is comparable to the rest of the industry: QTTB outperforms 43.34% of its industry peers.
QTTB has a Debt/Equity ratio of 0.61. This is a neutral value indicating QTTB is somewhat dependend on debt financing.
QTTB has a Debt to Equity ratio of 0.61. This is in the lower half of the industry: QTTB underperforms 76.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Altman-Z -3.75
ROIC/WACCN/A
WACC9.44%
QTTB Yearly LT Debt VS Equity VS FCFQTTB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 6.53 indicates that QTTB has no problem at all paying its short term obligations.
The Current ratio of QTTB (6.53) is better than 65.01% of its industry peers.
A Quick Ratio of 6.53 indicates that QTTB has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.53, QTTB is doing good in the industry, outperforming 65.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.53
Quick Ratio 6.53
QTTB Yearly Current Assets VS Current LiabilitesQTTB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for QTTB have decreased by -2.37% in the last year.
The Revenue for QTTB has decreased by -100.00% in the past year. This is quite bad
Measured over the past years, QTTB shows a very negative growth in Revenue. The Revenue has been decreasing by -26.31% on average per year.
EPS 1Y (TTM)-2.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.77%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-24.63%
Revenue growth 5Y-26.31%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 22.47% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad
EPS Next Y78.62%
EPS Next 2Y35.98%
EPS Next 3Y22.47%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
QTTB Yearly Revenue VS EstimatesQTTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
QTTB Yearly EPS VS EstimatesQTTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QTTB. In the last year negative earnings were reported.
Also next year QTTB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QTTB Price Earnings VS Forward Price EarningsQTTB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QTTB Per share dataQTTB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as QTTB's earnings are expected to grow with 22.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.98%
EPS Next 3Y22.47%

More info and screens

0

5. Dividend

5.1 Amount

QTTB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Q32 BIO INC

NASDAQ:QTTB (2/21/2025, 8:00:01 PM)

After market: 2.45 -0.12 (-4.67%)

2.57

+0.14 (+5.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)05-07 2025-05-07
Inst Owners74.57%
Inst Owner Change-92.25%
Ins Owners0.61%
Ins Owner Change2.66%
Market Cap31.30M
Analysts80
Price Target10 (289.11%)
Short Float %14.72%
Short Ratio2.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.74%
Min EPS beat(2)-33.54%
Max EPS beat(2)-1.95%
EPS beat(4)1
Avg EPS beat(4)-139.46%
Min EPS beat(4)-530.86%
Max EPS beat(4)8.5%
EPS beat(8)2
Avg EPS beat(8)-78.26%
EPS beat(12)5
Avg EPS beat(12)-49.35%
EPS beat(16)9
Avg EPS beat(16)-28.93%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-43.68%
PT rev (3m)-87.4%
EPS NQ rev (1m)-11.99%
EPS NQ rev (3m)-21.19%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.71
P/tB 1.71
EV/EBITDA N/A
EPS(TTM)-22.87
EYN/A
EPS(NY)-4.04
Fwd EYN/A
FCF(TTM)-6.4
FCFYN/A
OCF(TTM)-6.39
OCFYN/A
SpS0
BVpS1.5
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.51%
ROE -271.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.34%
ROA(5y)-52.65%
ROE(3y)-71.33%
ROE(5y)-63.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.53
Quick Ratio 6.53
Altman-Z -3.75
F-Score2
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)56.06%
Cap/Depr(5y)112.08%
Cap/Sales(3y)22.33%
Cap/Sales(5y)302.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.77%
EPS Next Y78.62%
EPS Next 2Y35.98%
EPS Next 3Y22.47%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-24.63%
Revenue growth 5Y-26.31%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y47.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.61%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.39%
OCF growth 3YN/A
OCF growth 5YN/A